Discover TCR mimic antibodies that Target Previously “Undruggable” Intracellular Proteins with Keyway™ TCR
Webinar Overview:
Unlock access to intracellular protein targets and maximize TCRm/TCR-based therapeutic antibody discovery with this presentation by Dr. Dongxing Zha that reveals how Alloy’s proprietary
Keyway™ TCRm Discovery Platform and expertise can:
- Overcome challenges to intracellular protein-targeted drug discovery: Learn how the Keyway™ TCRm Discovery Platform identifies TCR mimic (TCRm) antibodies that target intracellular antigens presented on cell surface MHC molecules (pMHC complexes) with high
- Identify highly-specific functional TCRm leads: Discover Alloy’s proprietary specificity screening and high-quality pMHC complex antigen production capabilities
- Accelerate immunotherapy development: Unleash the potential for development of antibody-like bispecific formats for simultaneous effector cell engagement and target engagement.
Webinar sample above. To access the full video content, fill out the form below.
About the Speaker:
Dongxing Zha, PhD
CTO, TCR Discovery & Engineering
Founder & CEO of Keyway TCR Discovery
Alloy Therapeutics
Dr. Dongxing Zha is the CEO of Keyway TCR Discovery at Alloy Therapeutics and is a seasoned drug development leader dedicated to the translation of immune-oncology discoveries into innovative anti-cancer therapies. Previously at MD Anderson Cancer Center, he oversaw a team that advanced the first TCRm to the clinic for treatment of various malignancies and was the leader of Oncology Research for Biologics and Immunotherapy Translation (ORBIT), a platform which develops biologic and cell-based therapies. Prior to that he served as a Research Fellow and Group Leader at Merck and a Senior Research Scientist at GlycoFi. Dr. Zha received his PhD in microbiology from Huazhong Agricultural University.
About the Speaker:
William “Beau” Carson IV, PhD
Senior Director, Head of
Translational Research
Alloy Therapeutics
Dr. William “Beau” Carson is the Senior Director, Head of Translational Research at Alloy Therapeutics, where he oversees the preclinical research team for vetting both in vitro and in vivo functional activity of antibody and cell-based modalities in a broad range of disease indications. Dr. Carson is a passionate immunologist with extensive experience in the complexities of immune response. He was previously a Principal Scientist and Senior Manager at Compass Therapeutics after serving as a Research Assistant Professor at the University of Michigan Medical School. Dr. Carson received his PhD in biomedical science-immunology from the University of Connecticut Health Center and worked as a Post Doctoral Fellow at the University of Michigan Medical School.
